Brief: Annexin Receives German Approval For ANXV Clinical Trial
May 11 (Reuters) - Annexin Pharmaceuticals AB (publ) ANNX.ST: RECEIVES GERMAN APPROVAL FOR ANXV CLINICAL TRIAL NEXUS PHASE 2A STUDY TO EXPAND TO GERMANY FOR RVO AND DR Source text: ID:nMFNQw4Zn Further company coverage: ANNX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Annexin Pharmaceuticals AB (publ)
See all newsBrief: Annexin Pharmaceuticals Q3 Net Loss At SEK 9.5 Mln
Brief: Annexin Pharmaceuticals Q2 2026 Net Loss SEK 11.6 Mln
Brief: Annexin Pharmaceuticals Gets International Nonproprietary Name Drug Candidate Anxv
Brief: Annexin Pharmaceuticals Updates On Nine Patients Treated In Nexus Study
Brief: Annexin's Rights Issue 98% Subscribed